ProCE Banner Activity

BIC/FTC/TAF vs DTG + FTC/TDF in Persons With HIV and HBV Coinfection: The Story So Far

Clinical Thought
Read my take on an interesting clinical presentation from the recent AIDS 2022 Conference in Montreal evaluating TDF vs TAF in HIV/HBV coinfection.

Released: August 19, 2022

Expiration: August 18, 2023

Share

Faculty

Jurgen Rockstroh

Jurgen Rockstroh, MD

Head of Infectious Diseases
Professor of Medicine 
Department of Medicine I
University Hospital Bonn
Bonn, Germany  

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Gilead Sciences, Inc.

ViiV Healthcare

Partners

IAS 2021

ProCE Banner

Faculty Disclosure

Primary Author

Jurgen Rockstroh, MD

Head of Infectious Diseases
Professor of Medicine 
Department of Medicine I
University Hospital Bonn
Bonn, Germany  

Jürgen K Rockstroh, MD: consultant/advisor/speaker: Abivax, Boehringer, Galapagos, Gilead, Janssen, Merck, Theratechnologies, Viiv.